CompletedNCT01809210SELECT-3Updated Mar 13, 2018Results posted

Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer

A Phase 1 interventional study of selumetinib and gemcitabine in Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV, sponsored by AstraZeneca. Completed at 4 sites in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-03-13.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Phase: Phase 1
Study type: Interventional
Enrollment: 55
Allocation: Not applicable
Ages: 18 Years to 99 Years
Sex: All

Study summary

This is a Phase I, open label multicentre study of selumetinib administered orally in combination with first line chemotherapy regimens to patients with advanced/metastatic NSCLC. The study has been designed to allow an investigation of the optimal dose of selumetinib in combination with various standard first line double-platinum chemotherapy regimens. Initial assessment will be based on tolerability of selumetinib in combination with one or more selected regimens that are considered to be tolerated also being assessed for preliminary evidence of activity.

This study is a dose finding and optional cohort expansion; In addition all patients will be assessed for anti-cancer efficacy of the combination of selumetinib and chemotherapy.

Read the detailed description

A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination with First Line Chemotherapy Regimens in Patients with Non-Small Cell Lung Cancer (NSCLC)

Conditions studied

Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV

Browse trials for

Keywords

MEK1/2 inhibitor,
Non Small Cell Lung Cancer,
metastatic,
first line treatment for Non Small Cell Lung Cancer

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's enrollment of 55 is close to the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.

Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 99 Years
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Provision of signed, written and dated consent prior to any study specific procedures
Male or female, aged 18 years or older
Histological or cytological confirmation of locally advanced or metastatic NSCLC (IIIB-IV)
Female patients must not be breast-feeding and have a negative pregnancy test prior to start of dosing or must have evidence of non-child-bearing potential
Patients must be eligible to receive treatment with the platinum doublet combination with which selumetinib is being combined and in accordance with the local product information

Exclusion criteria

Exclusion Criteria:

Prior chemotherapy or other systemic anti-cancer treatment for advanced NSCLC.
Prior surgery or radiotherapy within 6 months or palliative radiotherapy within 4 weeks of start of study treatment.
Female patients who are breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control
Another primary malignancy within 5 years of starting study treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ.
As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, active bleeding diatheses, renal transplant, or active infection

Study design

Phase: Phase 1
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrollment: 55 participants (actual)

Study arms

Experimental
Selumetinib+standard chemotherapy
Selumetinib plus gemcitabine; or pemetrexed and cisplatin or carboplatin
Drug: selumetinib · Drug: gemcitabine · Drug: cisplatin · Drug: carboplatin · Drug: pemetrexed

Interventions

Drugselumetinib
2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy
Druggemcitabine
1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
Drugcisplatin
75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
Drugcarboplatin
If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle
Drugpemetrexed
Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.

What researchers measure

Primary outcomes

Dose Limiting Toxicity (DLT) Events in Chemotherapy in Combination With Selumetinib
Any toxicity not attributable to the disease or disease-related processess under investigation, considered related to the combination of chemotherapy plus selumetinib, which occurs within the timeframe and is dose limiting
Time frame: The first dose on Cycle 1 Day 1 up to the time before dosing on Cycle 2 Day 1, assessed up to 3 weeks

Secondary outcomes

Best Objective Response
The best response a patient has had during their time in the study up until RECIST progression or last valuable assessment in the absence of RECIST progression. Per Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progressive Disease (PD); Progressive Disease (PD), \>=20% increase in the sum of the longest diameter of target lesions, the sum must also demonstrate an absolute increase of \>=5mm; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm
Time frame: Screening, week 6 and week 12
Percentage Change From Baseline at 6 Weeks in Target Lesion Size
The percentage change in the sum of the diameters of target lesions
Time frame: Week 6
Best Percentage Change From Baseline in Target Lesion Size
The best percentage change in tumour size a patient has had during their time in the study up until RECIST progression or last valuable assessment in the absence of RECIST progression. Percentage change was derived at each visit by the percentage change in the sum of the diameters of target lesions
Time frame: Screening, week 6 and week 12
Objective Response Rate (ORR)
The number of patients who had at least 1 confirmed visit response of Complete Response (CR) or Partial Response (PR) prior to any evidence of progression. Per Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm; Objective Response Rate (ORR) = CR + PR
Time frame: Up until progression or last evaluable assessment in the absence of progression, up to 9 months
AUC (0-tau)
Area under the concentration time curve (AUC) over a dosing interval at steady state (0-tau)
Time frame: Cycle 2 Day1, pre-dose, 0.5, 1, 1.5, 2, 4, 8, 10 hours post dose
Cmax,ss
Maximum plasma concentration at steady state
Time frame: Cycle 2 Day1, pre-dose, 0.5, 1, 1.5, 2, 4, 8, 10 hours post dose
Tmax,ss
Time to reach maximum plasma concentration at steady state
Time frame: Cycle 2 Day1, pre-dose, 0.5, 1, 1.5, 2, 4, 8, 10 hours post dose
CL/F
Apparent oral plasma clearance
Time frame: Cycle 2 Day1, pre-dose, 0.5, 1, 1.5, 2, 4, 8, 10 hours post dose

Results

Posted Mar 13, 2018

Participant flow

Patients were enrolled into dose-finding cohorts to evaluate escalating doses of selumetinib (AZD6244; ARRY-142886) to determine the maximum tolerated dose in combination with standard first-line chemotherapy regimens. Chemotherapy was administered on Day 1 (and Day 8 for gemcitabine) of each 3-week cycle.

Participant flow — Overall Study
Milestone	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
Started	3	9	7	3	6	15	12
Completed	2	8	4	2	4	12	7
Not completed	1	1	3	1	2	3	5
Withdrew: Withdrawal by subject	0	0	1	1	1	0	4
Withdrew: Death	1	1	2	0	1	3	1

Outcome measures

PrimaryDose Limiting Toxicity (DLT) Events in Chemotherapy in Combination With Selumetinib

Any toxicity not attributable to the disease or disease-related processess under investigation, considered related to the combination of chemotherapy plus selumetinib, which occurs within the timeframe and is dose limiting

Time frame:: The first dose on Cycle 1 Day 1 up to the time before dosing on Cycle 2 Day 1, assessed up to 3 weeks
Reported as:: Number · participants

Dose Limiting Toxicity (DLT) Events in Chemotherapy in Combination With Selumetinib
participants	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
Evaluable patients	3	7	4	3	6	12	6
Evaluable patients with a DLT Event	0	2	1	0	0	1	1

SecondaryBest Objective Response

The best response a patient has had during their time in the study up until RECIST progression or last valuable assessment in the absence of RECIST progression. Per Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progressive Disease (PD); Progressive Disease (PD), \>=20% increase in the sum of the longest diameter of target lesions, the sum must also demonstrate an absolute increase of \>=5mm; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm

Time frame:: Screening, week 6 and week 12
Reported as:: Number · participants

Best Objective Response
participants	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
Complete response	0	0	0	0	0	0	0
Partial response	1	2	2	1	1	2	2
Unconfirmed complete or partial response	0	3	0	0	2	2	2
Stable disease	0	1	2	2	3	7	6
RECIST progression	2	0	1	0	0	1	1
Death	0	0	0	0	0	1	0
Incomplete post-baseline assessments	0	3	2	0	0	2	1

SecondaryPercentage Change From Baseline at 6 Weeks in Target Lesion Size

The percentage change in the sum of the diameters of target lesions

Time frame:: Week 6
Reported as:: Mean · % change

Percentage Change From Baseline at 6 Weeks in Target Lesion Size
% change	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
Percentage Change From Baseline at 6 Weeks in Target Lesion Size	-7.5 ± 19.79	-29.3 ± 11.15	-10.4 ± 24.45	-14.7 ± 1.91	-24.4 ± 32.60	-18.9 ± 10.55	-18.4 ± 19.58

SecondaryBest Percentage Change From Baseline in Target Lesion Size

The best percentage change in tumour size a patient has had during their time in the study up until RECIST progression or last valuable assessment in the absence of RECIST progression. Percentage change was derived at each visit by the percentage change in the sum of the diameters of target lesions

Time frame:: Screening, week 6 and week 12
Reported as:: Mean · % change

Best Percentage Change From Baseline in Target Lesion Size
% change	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
Best Percentage Change From Baseline in Target Lesion Size	-11.9 ± 26.52	-34.6 ± 8.11	-41.3 ± 21.25	-28.3 ± 15.25	-34.7 ± 33.30	-24.4 ± 14.71	-25.4 ± 20.51

SecondaryObjective Response Rate (ORR)

The number of patients who had at least 1 confirmed visit response of Complete Response (CR) or Partial Response (PR) prior to any evidence of progression. Per Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) for target lesions (TL) and assessed by MRI or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Complete Response (CR), disappearance of all target lesions, any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm; Objective Response Rate (ORR) = CR + PR

Time frame:: Up until progression or last evaluable assessment in the absence of progression, up to 9 months
Reported as:: Number · participants

Objective Response Rate (ORR)
participants	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
Objective Response Rate (ORR)	1 ± 26.52	2 ± 8.11	2 ± 21.25	1 ± 15.25	1 ± 33.30	2 ± 14.71	2 ± 20.51

SecondaryAUC (0-tau)

Area under the concentration time curve (AUC) over a dosing interval at steady state (0-tau)

Time frame:: Cycle 2 Day1, pre-dose, 0.5, 1, 1.5, 2, 4, 8, 10 hours post dose
Reported as:: Geometric mean · h*ng/mL

AUC (0-tau)
h*ng/mL	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
AUC (0-tau)	NA ± NA	3571 ± 42.13	3339 ± 15.08	4813 ± 30.93	4366 ± 48.14	4116 ± 33.92	5202 ± 52.94

SecondaryCmax,ss

Maximum plasma concentration at steady state

Time frame:: Cycle 2 Day1, pre-dose, 0.5, 1, 1.5, 2, 4, 8, 10 hours post dose
Reported as:: Geometric mean · ng/mL

Cmax,ss
ng/mL	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
Cmax,ss	476.7 ± 51.12	1222 ± 59.86	1487 ± 23.09	1615 ± 27.71	1375 ± 40.21	1364 ± 57.78	2309 ± 35.99

SecondaryTmax,ss

Time to reach maximum plasma concentration at steady state

Time frame:: Cycle 2 Day1, pre-dose, 0.5, 1, 1.5, 2, 4, 8, 10 hours post dose
Reported as:: Median · h

Tmax,ss
h	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
Tmax,ss	1.00 ± 51.12	1.25 ± 23.09	1.00 ± 57.78	1.00 ± 59.86	1.75 ± 27.71	1.48 ± 40.21	1.50 ± 35.99

SecondaryCL/F

Apparent oral plasma clearance

Time frame:: Cycle 2 Day1, pre-dose, 0.5, 1, 1.5, 2, 4, 8, 10 hours post dose
Reported as:: Mean · L/h

CL/F
L/h	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
CL/F	NA ± NA	14.72 ± 5.156	22.64 ± 3.521	10.72 ± 3.328	18.82 ± 9.777	19.08 ± 5.881	21.02 ± 9.857

Adverse events

Collected over Adverse Events are collected throughout the study, from informed consent until the end of follow-up, which is defined as 28 +/- 7 days after selumetinib is discontinued. Patients were expected to receive up to 6 cycles (18 wks) of chemotherapy.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
Group	Deaths	Serious	Other
Cohort 1 sel50, Gem, Cis	—	1/3 (33.3%)	3/3 (100%)
Cohort 2 sel50, Gem, Carb	—	6/9 (66.7%)	9/9 (100%)
Cohort 3 sel75, Gem, Cis	—	3/7 (42.9%)	7/7 (100%)
Cohort 4 sel150, Pem, Carb	—	2/3 (66.7%)	3/3 (100%)
Cohort 5 sel75, Pem, Carb	—	3/6 (50%)	6/6 (100%)
Cohort 6 sel75, Pem, Cis	—	9/15 (60%)	15/15 (100%)
Cohort 7 sel100, Pem, Carb	—	9/12 (75%)	12/12 (100%)

Most frequent serious events

Showing 10 of 34

Most frequent serious events
Event	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
ThrombocytopeniaBlood and lymphatic system disorders	0/3	4/9	0/7	0/3	0/6	0/15	4/12
Large intestine perforationGastrointestinal disorders	1/3	0/9	1/7	0/3	0/6	0/15	0/12
Musculoskeletal chest painMusculoskeletal and connective tissue disorders	0/3	0/9	0/7	1/3	0/6	0/15	0/12
Pain in extremityMusculoskeletal and connective tissue disorders	0/3	0/9	0/7	1/3	0/6	0/15	0/12
Urinary retentionRenal and urinary disorders	0/3	0/9	0/7	1/3	0/6	0/15	0/12
Pulmonary embolismRespiratory, thoracic and mediastinal disorders	1/3	0/9	1/7	0/3	0/6	0/15	0/12
NauseaGastrointestinal disorders	0/3	0/9	2/7	0/3	0/6	1/15	0/12
AnaemiaBlood and lymphatic system disorders	0/3	0/9	1/7	0/3	0/6	0/15	2/12
PyrexiaGeneral disorders	0/3	1/9	0/7	0/3	1/6	0/15	0/12
Neutropenic sepsisInfections and infestations	0/3	0/9	0/7	0/3	1/6	0/15	0/12

Most frequent other events

Showing 10 of 174

Most frequent other events
Event	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb
NauseaGastrointestinal disorders	3/3	5/9	5/7	3/3	5/6	8/15	10/12
VomitingGastrointestinal disorders	3/3	4/9	4/7	1/3	4/6	6/15	7/12
ConstipationGastrointestinal disorders	1/3	5/9	4/7	2/3	2/6	6/15	9/12
RashSkin and subcutaneous tissue disorders	0/3	3/9	5/7	2/3	1/6	8/15	6/12
Periorbital oedemaEye disorders	0/3	3/9	2/7	2/3	1/6	2/15	6/12
DiarrhoeaGastrointestinal disorders	2/3	5/9	4/7	1/3	3/6	9/15	6/12
FatigueGeneral disorders	2/3	6/9	3/7	1/3	2/6	9/15	7/12
Lower respiratory tract infectionInfections and infestations	0/3	4/9	1/7	2/3	0/6	2/15	0/12
HypomagnesaemiaMetabolism and nutrition disorders	0/3	0/9	0/7	2/3	0/6	0/15	0/12
AnaemiaBlood and lymphatic system disorders	1/3	5/9	0/7	1/3	1/6	0/15	4/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb	Total
Mean	58.7 ± 3.79	69.2 ± 3.53	55.1 ± 8.65	64.7 ± 7.23	59.5 ± 5.28	61.8 ± 5.86	60.2 ± 8.39	61.5 ± 7.45

Sex: Female, Male
Sex: Female, Male(Participants)	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb	Total
Female	1	5	3	1	4	5	7	26
Male	2	4	4	2	2	10	5	29

Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)	Cohort 1 sel50, Gem, Cis	Cohort 2 sel50, Gem, Carb	Cohort 3 sel75, Gem, Cis	Cohort 4 sel150, Pem, Carb	Cohort 5 sel75, Pem, Carb	Cohort 6 sel75, Pem, Cis	Cohort 7 sel100, Pem, Carb	Total
Black Or African American	1	0	0	0	1	1	0	3
Other	0	0	0	0	0	1	1	2
White	2	9	7	3	5	13	11	50

Study locations

4 sites

Research Site
Glasgow, G12 0YN, United Kingdom
Research Site
London, W1G 6AD, United Kingdom
Research Site
Manchester, M20 4BX, United Kingdom
Research Site
Newcastle upon Tyne, NE7 7DN, United Kingdom

References and documents

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Mar 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01809210
Lead sponsor: AstraZeneca
Responsible party: Sponsor
First posted: Mar 12, 2013
Start date: Apr 4, 2013
Primary completion: Jan 4, 2016
Completion: Jan 4, 2016
Results posted: Mar 13, 2018
Last update: Mar 13, 2018

Study contacts

Gabriella Mariani, MD

study director · AstraZeneca UK, MSD

Emma Dean, BMEDSCI, BM, BS, PHD

principal investigator · The Christie NHS Foundation Trust, UK

Fiona Blackhall, PhD, FRCP

principal investigator · The Christie NHS Foundation Trust Clinical Trials Unit; UK

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Neoplasms→

Other studies from this sponsor

AstraZeneca

Start the discussion